A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann. Oncol. 25(8), 1650–1656 (2014).
  Medline CASGoogle Scholar
• 3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913–2921 (2014).
  Medline CASGoogle Scholar
• 4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
  MedlineGoogle Scholar
• 5. Salvia R, Fernández-Del Castillo C, Bassi C et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann. Surg. 239(5), 678 (2004).
  MedlineGoogle Scholar
• 6. National Cancer Institute. Cancer stat facts: cancer of the pancreas. Surveillance: Epidemiology, and End Results Program. (2017). https://seer.cancer.gov/statfacts/html/pancreas.html
  Google Scholar
• 7. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369(18), 1691–1703 (2013). • Phase III clinical trial that demonstrates a new regimen for first-line treatment of metastatic pancreatic cancer.
  Medline CASGoogle Scholar
• 8. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817–1825 (2011). • Phase III clinical trial that demonstrates the efficacy of FOLFIRINOX in the treatment of first-line metastatic pancreatic cancer.
  Medline CASGoogle Scholar
• 9. Wang-Gillam A, Li C-P, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase III trial. Lancet 387(10018), 545–557 (2016).
  Medline CASGoogle Scholar
• 10. Bailey P, Chang DK, Nones K et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592), 47 (2016).
  Medline CASGoogle Scholar
• 11. Waddell N, Pajic M, Patch AM et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540), 495–501 (2015).
  Medline CASGoogle Scholar
• 12. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415 (2013).
  Medline CASGoogle Scholar
• 13. Consortium BCL. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91(15), 1310–1316 (1999).
  MedlineGoogle Scholar
• 14. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94(18), 1358–1365 (2002).
  Medline CASGoogle Scholar
• 15. Holter S, Borgida A, Dodd A et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J. Clin. Oncol. 33(28), 3124–3129 (2015). • Prevalence of germline BRCA mutations in pancreatic cancer.
  Medline CASGoogle Scholar
• 16. Golan T, Kindler HL, Park JO et al. Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized Phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). J. Clin. Oncol. 36(Suppl. 15), 4115 (2018).
  Google Scholar
• 17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 18. Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16(2), 81–104 (2019).
  Medline CASGoogle Scholar
• 19. Golan T, Kanji ZS, Epelbaum R et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br. J. Cancer 111(6), 1132–1138 (2014). • Clinical characteristics of BRCA-mutated patients.
  Medline CASGoogle Scholar
• 20. Pishvaian MJ, Blais EM, Brody JR et al. Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the Know Your Tumor Program. JCO Precision Oncol. 3, 1–10 (2019).
  Google Scholar
• 21. Dobzhansky TJG. Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. 31(3), 269 (1946).
  Google Scholar
• 22. Lord CJ, Ashworth A. PARP inhibitors: the first synthetic lethal targeted therapy. Science (New York, NY) 355(6330), 1152 (2017).
  CASGoogle Scholar
• 23. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434(7035), 913 (2005).
  Medline CASGoogle Scholar
• 24. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917 (2005).
  Medline CASGoogle Scholar
• 25. Yelamos J, Farres J, Llacuna L, Ampurdanes C, Martin-Caballero J. PARP-1 and PARP-2: new players in tumour development. 1(3), 328 (2011).
  Google Scholar
• 26. Murai J, Shar-Yin NH, Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72(21), 5588–5599 (2012).
  Medline CASGoogle Scholar
• 27. Lord CJ, Ashworth AJS. PARP inhibitors: the first synthetic lethal targeted therapy. 355(6330), 1152 (2017).
  Google Scholar
• 28. Ceccaldi R, Rondinelli B, D'Andrea ADJTICB. Repair pathway choices and consequences at the double-strand break. 26(1), 52–64 (2016).
  Google Scholar
• 29. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123–134 (2009).
  Medline CASGoogle Scholar
• 30. Menear KA, Adcock C, Boulter R et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J. Med. Chem. 51(20), 6581–6591 (2008).
  Medline CASGoogle Scholar
• 31. Rolfo C, Swaisland H, Leunen K et al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv. Ther. 32(6), 510–522 (2015).
  Medline CASGoogle Scholar
• 32. Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14(12), 3916–3925 (2008).
  Medline CASGoogle Scholar
• 33. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. 105(44), 17079–17084 (2008).
  Medline CASGoogle Scholar
• 34. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123–134 (2009).
  Medline CASGoogle Scholar
• 35. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33(3), 244–250 (2014). •• First study that shows activity of olaparib in pancreatic cancer.
  MedlineGoogle Scholar
• 36. Golan T, Hammel P, Reni M et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381(4), 317 (2019). •• Phase III clinical trial that demonstrates efficacy of olaparib manteinance in metastatic pancreatic cancer.
  Medline CASGoogle Scholar
• 37. Heo Y-A, Dhillon S. Olaparib tablet: a review in ovarian cancer maintenance therapy. Target. Oncol. 13(6), 801–808 (2018).
  MedlineGoogle Scholar
• 38. Teresa Macarulla HLK, Pascal Hammel, Michele Reni et al. Early progression in patients with metastatic pancreatic cancer anda germline BRCA mutation: Phase III Polo trial of olaparib versus placebo. J. Clin. Oncol. 38(Suppl. 4), 750 (2020).
  Google Scholar
• 39. Michele Reni HLK, Pascal Hammel, Eric van Cutsem et al. Adverse events with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial. J. Clin. Oncol. 38(Suppl. 4), 686 (2020).
  MedlineGoogle Scholar
• 40. Shroff RT, Hendifar A, Mcwilliams RR et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precision Oncol. 2, 1–15 (2018).
  MedlineGoogle Scholar
• 41. Binder KaR, Mick R, O'Hara M et al. A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2, PALB2. Presented at: Cancer Research. GA, USA (2019).
  Google Scholar
• 42. O'reilly EM, Lee JW, Lowery MA et al. Phase I trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 124(7), 1374–1382 (2018).
  MedlineGoogle Scholar
• 43. Golan T, Varadhachary GR, Sela T et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J. Clin. Oncol. 36(Suppl. 4), 297 (2018).
  Google Scholar
• 44. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat. Rev. Clin. Oncol. 17, 1–16 (2019).
  Google Scholar
• 45. Kristeleit R, Shapiro GI, Burris HA et al. A Phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin. Cancer Res. 23(15), 4095–4106 (2017).
  Medline CASGoogle Scholar
• 46. Swisher EM, Lin KK, Oza AM et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, Phase II trial. Lancet Oncol. 18(1), 75–87 (2017).
  Medline CASGoogle Scholar
• 47. O'reilly EM, Lee JW, Zalupski M et al. Randomized, multicenter, Phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J. Clin. Oncol. 38(13), 1378–1388 (2020).
  MedlineGoogle Scholar